BioCryst Pharmaceuticals Inc BCRX

Healthcare Biotechnology

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and injectable protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhibitor for diabetic macular edema that is in preclinical phase; and BCX10013, an oral Factor D inhibitor for complement-mediated diseases, as well as developing Oral C5 Inhibitor and Oral C2 Inhibitor. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Shionogi & Co., Ltd., Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Autho...

NDAQ:BCRX - Post by User

BioCryst Pharmaceuticals Inc

<< Previous

Bullboard Posts

Next >>

(78)
•••

Post by davgroon Apr 11, 2020 11:15am

221 Views

Post# 30898832

BioCryst Shares Surged 35% After Hours on Thursday

BioCryst stock rallies on start of coronavirus drug study

Published: April 9, 2020 at 5:52 p.m. ET
BioCryst Pharmaceuticals Inc. BCRX,

+3.50%

shares rallied in the extended session Thursday after the drug maker said it was starting a clinical trial to test its COVID-19 treatment. BioCryst shares surged 35% after hours, following a 3.5% rise to close the regular session at $2.07. The company said it opened a randomized, double-blind, placebo-controlled clinical trial to test the drug galidesivir in treating patients with COVID-19. The study, which is being funded by the U.S. National Institutes of Health's National Institute of Allergy and Infectious Diseases, will be conducted in Brazil, the company said. Many drug companies have recently started development of either COVID-19 treatments or vaccines.

https://www.marketwatch.com/story/biocryst-stock-rallies-on-start-of-coronavirus-drug-study-2020-04-09

<< Previous

Bullboard Posts

Next >>

Tajiri Resources strikes gold near major players in Guyana